Skip to main content

Environmental Stewardship:
A Key Ingredient of Our Medicines

We have set—and exceeded—ambitious targets for environmental performance, and we will build on these achievements to challenge ourselves and our vendors to continue reducing environmental impact and incorporating sustainability across our global enterprise. We incorporate the principles of green chemistry and green engineering to reduce our environmental impact across the supply chain: from product design, through manufacture, packaging and transport. And we are working to reduce the environmental impact of packaging of our products by using more recycled materials in our primary and secondary packaging, reducing the amount of secondary packaging and optimizing the design of packaging inserts.

GREENHOUSE GAS (GHG) REDUCTION

18%

18% reduction in absolute GHG emissions (against 5% goal)

50%

50% decrease in transportation-related GHG emissions for Orencia® and Opdivo®

20%

20% of BMS energy is cogenerated

PRODUCT DEVELOPMENT, PACKAGING, LABELLING AND TRANSPORT

100%

100% of new products in our R&D portfolio are assessed for improved environmental impact

100% of prioritized product packaging is assessed for improved environmental impact

Implemented e-labeling of Opdivo® to provide a single, digital source of information for product details and updates and to save package-insert materials

Shifting to cleaner liquid natural gas as fuel in our distribution networks

WATER MANAGEMENT

100%

100% of our manufacturing sites evaluated for waste-water practices (3-year study completed across 13 sites in 6 countries)

6%

6% reduction in water usage from 2015 baseline (against 5% goal)

PRACTICES & INNOVATIONS

US green building council

12 LEED certifications received since 2009 (2 additional pending)

energy star

Awarded Energy Star Partner of the Year for 5 consecutive years and Sustained Excellence for 2 consecutive years

The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com